Who Owns Vericel Company?

Vericel Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Vericel?

Unraveling the Vericel SWOT Analysis is just the beginning. Understanding the Vericel ownership structure is key to grasping its strategic moves and future prospects. This deep dive into Who owns Vericel will reveal the key players shaping this biopharmaceutical innovator. Discover the forces driving Vericel company forward.

From its roots as Aastrom Biosciences to its current status, Vericel's ownership has transformed. This analysis will examine the evolution of Vericel investors and Vericel shareholders, providing insights into the company's financial performance and strategic direction. Learn how to find Vericel company ownership details and understand the influence of its major stakeholders and the Vericel stock.

The story of Vericel Corporation begins with Aastrom Biosciences, Inc., established in Ann Arbor, Michigan, in 1989. While the specific founders and their initial ownership details aren't widely available, the company's trajectory changed significantly in 2014. This transformation laid the groundwork for the Vericel we know today.

A pivotal moment for the company arrived in May 2014. Aastrom Biosciences acquired Sanofi's cell therapy and regenerative medicine business unit. This strategic move included products like Carticel, Epicel, and MACI. This acquisition reshaped Aastrom's structure, dramatically increasing its employee base and introducing revenue-generating products, effectively transitioning it from a development-stage entity to a commercial operation.

In October 2014, Aastrom Biosciences rebranded as Vericel Corporation and relocated its headquarters to Cambridge, Massachusetts. The leadership team from Aastrom Biosciences spearheaded this crucial acquisition and rebranding. They integrated key personnel with experience in the acquired cell therapies from Genzyme, which Sanofi had acquired in 2011. This strategic shift marked the beginning of Vericel's current form.

Aastrom Biosciences' Foundation

Aastrom Biosciences was founded in 1989 in Ann Arbor, Michigan. The company's initial focus was on cell therapy and regenerative medicine. The founders' identities and initial equity splits are not widely available.

The 2014 Acquisition

In May 2014, Aastrom acquired Sanofi's cell therapy business unit. This included products like Carticel, Epicel, and MACI. This acquisition was a turning point, providing established products and revenue.

Rebranding to Vericel

October 2014 marked the rebranding of Aastrom Biosciences to Vericel Corporation. The headquarters were relocated to Cambridge, Massachusetts. This change reflected the company's new focus and direction.

Leadership Transition

The leadership from Aastrom Biosciences oversaw the acquisition and rebranding. Key personnel with experience from Genzyme, which Sanofi had acquired, were integrated. This ensured continuity and expertise.

Product Portfolio Expansion

The acquisition of Sanofi's unit significantly expanded Vericel's product portfolio. The addition of Carticel, Epicel, and MACI provided immediate revenue streams. This diversified the company's offerings.

From Development to Commercial

The acquisition propelled Aastrom from a development-stage company to a commercial operation. This shift allowed Vericel to generate revenue from established products. This increased the company's market presence.

Ownership and Key Highlights

Understanding the history of Vericel ownership requires looking back at Aastrom Biosciences' transformation. The 2014 acquisition and rebranding were critical events. The company's evolution underscores the importance of strategic acquisitions in the biotech industry. For more insights into the Vericel company and its strategic direction, consider exploring the Target Market of Vericel.

• Aastrom Biosciences was founded in 1989.
• The Sanofi acquisition occurred in May 2014.
• The rebranding to Vericel happened in October 2014.
• Vericel's headquarters are located in Cambridge, Massachusetts.

Vericel SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The story of Who owns Vericel began with its initial public offering (IPO) on February 4, 1997, when it was known as Aastrom Biosciences, Inc. A significant transformation in Vericel ownership happened in 2014. This was when the company acquired Sanofi's cell therapy and regenerative medicine business. This acquisition was a pivotal moment, transitioning the company into a commercial-stage entity.

The evolution of Vericel company reflects strategic shifts and expansions. The company's ownership structure has been shaped by key acquisitions and the influence of major shareholders. This has positioned Vericel in the biopharmaceutical market.

As of June 13, 2025, Vericel's market capitalization was approximately $2.15 billion. Vericel investors and Vericel shareholders include significant institutional investors like BlackRock, Vanguard, and others. These investors collectively hold a substantial portion of the company's shares. The influence of these major stakeholders is critical to the company's strategic decisions. For more insights, you can explore the Competitors Landscape of Vericel.

Key Takeaways on Vericel Ownership

Vericel's ownership structure is primarily influenced by institutional investors and mutual funds.

• The acquisition of Sanofi's cell therapy business in 2014 was a major turning point.
• Institutional investors like BlackRock and Vanguard hold significant shares.
• Vericel's market capitalization reflects its position in the biopharmaceutical sector.
• Insider holdings are a smaller percentage compared to institutional ownership.

Vericel PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors significantly influences the strategic direction and governance of the Vericel company. The leadership team includes Dominick Colangelo as President and CEO, Joseph Mara as Chief Financial Officer, and Michael Halpin as Chief Operating Officer. Key personnel also feature Karen Mahoney (Chief Human Resources Officer), Sean C. Flynn (Chief Legal Officer), and Jonathan Mark Hopper (Chief Medical Officer). Robert L. Zerbe serves as the Independent Chairman of the Board, alongside independent directors such as Heidi M. Hagen, Kevin F. Mclaughlin, Alan L. Rubino, and Paul K. Wotton. This structure combines executive leadership with independent oversight, a common setup for publicly traded entities. Details on the board's activities and shareholder proposals are available in SEC filings, such as the DEF 14A proxy statement filed on March 20, 2025, for the Annual Meeting of Shareholders held on April 30, 2025.

The board's composition and the structure of its committees are designed to ensure effective corporate governance. The independent directors play a crucial role in overseeing management and representing the interests of Vericel shareholders. The company’s commitment to transparency and adherence to regulatory standards is evident through its SEC filings and the information provided in its annual reports. These documents are essential resources for Vericel investors seeking detailed insights into the company's governance practices and financial performance.

Regarding Vericel ownership and voting power, the company's structure appears to follow a standard one-share-one-vote model, given its public listing on NASDAQ and the absence of information suggesting dual-class shares or special voting rights. SEC filings provide detailed information on director elections and other governance matters. For instance, some Section 16 officers or directors adopted Rule 10b5-1 trading arrangements in March 2025 for potential future stock sales. For more detailed information about the company, you can read this article about the Vericel company.

Voting Rights and Governance

The voting structure at Vericel is typically one share, one vote, reflecting standard practices for publicly traded companies. Details on director elections and governance are found in SEC filings.

• Independent directors ensure oversight.
• SEC filings provide governance details.
• Rule 10b5-1 trading arrangements were adopted by some officers in March 2025.
• Shareholders can review the DEF 14A proxy statement for comprehensive information.

Vericel Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership structure of the Vericel company has been shaped by consistent growth and strategic initiatives. In 2024, the company demonstrated robust financial performance, with a 20% increase in total revenue, reaching over $237 million. This strong performance led to GAAP profitability, with a net income of $10.4 million. The company ended 2024 with approximately $167 million in cash, restricted cash, and investments. This financial stability is a key factor influencing the Vericel ownership profile.

Looking ahead, Vericel anticipates continued growth. Total net revenue growth for 2025 is expected to be between 20% and 23%. The company is also progressing with its MACI Ankle clinical study, expected to begin in the second half of 2025, targeting an addressable market of $1 billion. The new corporate headquarters and manufacturing facility, substantially completed at the end of 2024, will begin commercial manufacturing in 2026, potentially enabling international expansion of MACI. These developments are likely to influence the interests of Vericel investors.

Institutional ownership remains a significant aspect of the Vericel ownership structure. As of June 11, 2025, 645 institutional owners held a total of 73,132,397 shares. Insider holdings have remained relatively stable, at 1.17% in May 2025. While routine insider stock sales have occurred under Rule 10b5-1 trading plans in early 2025, no major share buybacks or secondary offerings have been highlighted. These trends suggest a focus on organic expansion and market penetration. For more insights into the company's strategic direction, you might find this article about the Growth Strategy of Vericel helpful.

Vericel Stock

Vericel stock is traded on the public market under the symbol VCEL. Current Vericel stock price history can be tracked through financial data providers.

Major Investors

Identifying who owns Vericel includes tracking institutional holdings. Information on Vericel shareholders and major investors can be found in SEC filings.

Company Leadership

The Vericel company leadership team is crucial. Information about who is the CEO of Vericel and other key executives can be found on the company's website.

Financial Information

Vericel company financial performance is reported in its Vericel company annual report. Detailed Vericel company ownership details can be found in these reports.

Vericel Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs